PHARMACOECONOMIC EVALUATION FOR DENGUE VACCINE PRICING FOR MALAYSIA: TOWARDS AFFORDABILITY, COST EFFECTIVENESS AND SUSTAINABILITY
DOI:
https://doi.org/10.22159/ajpcr.2017v10s3.21352Keywords:
Pharmacoeconomics, Sustainable dengue vaccine, DALYAbstract
Objective: Malaysian health ministry is currently evaluating the licensing of dengue vaccine Dengvaxia using a set of criteria including safety, efficacy and cost-effectiveness. The purpose of this research is to formulate a model framework to assist transparent decision-making.
Methods: To quantify the cost-effective price of vaccine, pharmacoeconomic evaluation models are commonly used. We review in this paper dengue economic burdens and pharmacoeconomic models, with particular reference to cost-effectiveness.
Results: A major weakness in current pharmacoeconomic models is the omission of cost of vaccine production, which is two orders of magnitude lower than the market price. This paper proposes an inclusive model that yields a highly cost-effective threshold price of dengue vaccine at USD 5 per dose for Malaysia.
Conclusion: At USD 5 per dose, Dengue vaccine will be fair, Affordable and sustainable.Downloads
References
HL Koh. SY the FluSiM simulation for Malaysia: towards improved pandemic surveillance. Int J Chem Eng Appl 2011;2:53-9.
YA Halasa, DS Shepard, W Zeng. Economic cost of dengue in puerto rico. Am J Trop Med Hyg 2012;86:745-52.
WHO. Global strategy for dengue prevention and control 2012-2020. Geneva: World Health Organization; 2012.
JA Suaya, DS Shepard, JB Siqueira, CT Martelli, LCS Lum, LH Tan, et al. Cost of dengue cases in eight countries in the Americas and Asia: a prospective study. Am J Trop Med Hyg 2009;80:846-55.
DS Shepard, EA Undurraga, YA Halasa. Economic and disease burden of dengue in Southeast Asia. PLoS Negl Trop Dis 2013;7:1-12.
RT Mahoney, DP Francis, NM Frazatti-Gallin, AR Precioso, I Raw, Watler P, et al. Cost of production of live attenuated dengue vaccines: a case study of the Instituto Butantan, Sao Paulo, Brazil. Vaccine 2012;30:4892-6.
J Halstead, SB Deen. The future of dengue vaccines. Lancet 2002;360:1234-45.
M Kaddar, S Schmitt, M Makinen, J Milstien. Global support for new vaccine implementation in middle-income countries. Vaccine 2013;31 Suppl 2:B81-B96.
S Ozawa, A Mirelman, ML Stack, DG Walker, OS Levine. Cost-effectiveness and economic benefits of vaccines in low-and middle-income countries: a systematic review. Vaccine 2012;31:96-108.
ME Beatty, P Beutels, MI Meltzer, DS Shepard, J Hombach, R Hutubessy, et al. Health economics of dengue: a systematic literature review and expert panel’s assessment. Am J Trop Med Hyg 2011;84:473-88.
LR Carrasco, LK Lee, VJ Lee, EE Ooi, DS Shepard, TL Thein, et al. Economic impact of dengue illness and the cost-effectiveness of future vaccination programs in Singapore. PLoS Neglected Trop Dis 2011;5:e1426.
DS Shepard, EA Undurraga, RS Lees, Y Halasa, LCS Lum, CW Ng. Use of multiple data sources to estimate the economic cost of dengue illness in Malaysia. Am J Trop Med Hyg 2012;87:796-805.
Shafie. Cost effective price of dengue vaccination in Malaysia. Personal communication; 2016.
L Coudeville, GP Garnett. Transmission dynamics of the four dengue serotypes in southern Vietnam and the potential impact of vaccination. PLoS One 2012;7:e51244.
HL Koh, SY Teh, DL De Angelis, J Jiang. Infectious diseases: surveillance, genetic modification and simulation. In: CA Brebbia, AJ Kassab, EA Divo. Editors. Disaster Management and Human Health Risk II. Boston: WIT Press; 2011. p. 245-256.
SC Chen, MH Hsieh. Modeling the transmission dynamics of dengue fever: Implications of temperature effects. Sci Total Environ 2012;431:385-91.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
